Correlation Between Checkpoint Therapeutics and Candel Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Checkpoint Therapeutics and Candel Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Checkpoint Therapeutics and Candel Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Checkpoint Therapeutics and Candel Therapeutics, you can compare the effects of market volatilities on Checkpoint Therapeutics and Candel Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Checkpoint Therapeutics with a short position of Candel Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Checkpoint Therapeutics and Candel Therapeutics.

Diversification Opportunities for Checkpoint Therapeutics and Candel Therapeutics

-0.8
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Checkpoint and Candel is -0.8. Overlapping area represents the amount of risk that can be diversified away by holding Checkpoint Therapeutics and Candel Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Candel Therapeutics and Checkpoint Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Checkpoint Therapeutics are associated (or correlated) with Candel Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Candel Therapeutics has no effect on the direction of Checkpoint Therapeutics i.e., Checkpoint Therapeutics and Candel Therapeutics go up and down completely randomly.

Pair Corralation between Checkpoint Therapeutics and Candel Therapeutics

Given the investment horizon of 90 days Checkpoint Therapeutics is expected to generate 3.36 times less return on investment than Candel Therapeutics. But when comparing it to its historical volatility, Checkpoint Therapeutics is 2.47 times less risky than Candel Therapeutics. It trades about 0.04 of its potential returns per unit of risk. Candel Therapeutics is currently generating about 0.05 of returns per unit of risk over similar time horizon. If you would invest  209.00  in Candel Therapeutics on August 30, 2024 and sell it today you would earn a total of  286.00  from holding Candel Therapeutics or generate 136.84% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy99.8%
ValuesDaily Returns

Checkpoint Therapeutics  vs.  Candel Therapeutics

 Performance 
       Timeline  
Checkpoint Therapeutics 

Risk-Adjusted Performance

19 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Checkpoint Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively unfluctuating basic indicators, Checkpoint Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point.
Candel Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Candel Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in December 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Checkpoint Therapeutics and Candel Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Checkpoint Therapeutics and Candel Therapeutics

The main advantage of trading using opposite Checkpoint Therapeutics and Candel Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Checkpoint Therapeutics position performs unexpectedly, Candel Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Candel Therapeutics will offset losses from the drop in Candel Therapeutics' long position.
The idea behind Checkpoint Therapeutics and Candel Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Other Complementary Tools

Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Bonds Directory
Find actively traded corporate debentures issued by US companies